Mathematical program for predicting the risk for progression of atrial fibrillation and its possible complications in patients with hypertension and concomitant extracardiac diseases

DOI: https://doi.org/10.29296/25877305-2022-08-06
Issue: 
8
Year: 
2022

Professor L. Khidirova(1), MD; Z. Osmieva(1); V. Lukinov(2)
1-Novosibirsk State Medical University, Mnstry of Health of Russia
2-Institute of Computational Mathematics and Mathematical Geophysics, Siberian Branch, Russian Academy of Sciences, Novosibirsk

Objective. To elaborate a personalized algorithm for predicting the progression of atrial fibrillation (AF) and the development of its complications in essential hypertension concurrent with extracardiac diseases. Subjects and methods. An observational cohort study involved 308 males aged 45–60 years with AF and hypertension concurrent with extracardiac diseases: diabetes mellitus (n=40), diffuse toxic goiter (n=42); hypothyroidism (HT; n=59), abdominal obesity (n=64), and chronic obstructive pulmonary disease (n=47). A comparison group consisted of 56 patients without extracardiac disease. The study assessed clinical, laboratory, and anthropometric data and 24-hour ECG monitoring and echocardiography readings. All statistical calculations were performed using the Rstudio program (USA). Results. Significant predictors of AF progression have been established, which include remodeling indicators: a 1-ng/l elevation of galectin-3 increases the risk of AF progression by 1.003 times (p=0.016); a 1-cm left atrial (LA) enlargement does by 2.67 times (p
Keywords: 
cardiology
atrial fibrillation
comorbidities
personalized assessment.

References: 
  1. Kobalava Z.D., Kokhan E.V., Kiyakbaev G.K. et al. Atrial fibrillation and arterial hypertension: gender differences of ventriculoatrial remodeling with preserved ejection fraction. Rational Pharmacotherapy in Cardiology. 2017; 13 (4): 541–9 (in Russ.). DOI: 10.20996/1819-6446-2017-13-4-541-549
  2. Lip G.Y.H. et al. Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardiaca y Electrofisiologia (SOLEACE). Europace. 2017; 19 (6): 891–911. DOI: 10.1093/europace/eux091
  3. Oganov R.G., Denisov I.N., Simanenkov V.I. et al. Comorbidities in practice. Clinical guidelines. Cardiovascular Therapy and Prevention. 2017; 16 (6): 5–56 (in Russ.). DOI: 10.15829/1728-8800-2017-6-5-56
  4. Dedov D.V., Ivanov A.P., Elgardt I.A. Recurrent atrial fibrillation predictors in patients with arterial hypertension: circadian heart rate variability analysis. Cardiovascular Therapy and Prevention. 2011; 10 (7): 45–8 (in Russ.).
  5. Sorokina V.N., Pavluyushchik E.A., Khapaliuk A.V. et al. Predictive Model of Arterial Hypertension Development. Medical Journal. 2016; 2:115–118 (in Russ.).
  6. Williams B. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018; 36 (10): 1953–2041. DOI: 10.1097/HJH.0000000000001940
  7. Dansson L. et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999; 353 (9153): 611–6. DOI: 10.1016/s0140-6736(98)05012-0
  8. Patel A. et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370 (9590): 829–40. DOI: 10.1016/S0140-6736(07)61303-8
  9. Shalnova S.A., Konradi A.O., Karpov Yu.A. et al. Cardiovascular mortality in 12 Russian Federation regions – participants of the “Cardiovascular disease epidemiology in Russian regions” study. Russian Journal of Cardiology. 2012; 5: 6–11 (in Russ.).
  10. Koval S.N., Snegurskaya I.A. Factors of Atrial Fibrillation Risk and Unsolved Prevention Problems. Arterial Hypertension. 2016; 4: 16–26.
  11. Seliverstov P., Bakaeva S., Shapovalov V. A telemedicine system in the assessment of risks for socially significant chronic non-communicable diseases. Vrach. 2020; 31 (10): 68–73 (in Russ.). DOI: 10.29296/25877305-2020-10-13
  12. Jain K.K. Personalized Medicine. Trends Mol Med. 2002; 4 (6): 548–58.
  13. Krysyuk O.B., Obrezan A.G., Panomarenko G.N. Problems of personified medicine in internal diseases. Vestnik SPbGU. 2006; 11 (1):16–21 (in Russ.).
  14. Herrmann S.M., Paul М. Studying genotype-phenotype relationships: cardiovascular disease as an example. J Mol Med. 2002; 80 (5): 282–9. DOI: 10.1007/s00109-002-0330-x
  15. Ginsburg G.S., McCarthy.I.J. Personalized medicine: Revolutionizing drug discovery and patient care. Trends Biotechnol. 2001; 19 (12): 491–6. DOI: 10.1016/s0167-7799(01)01814-5
  16. Lindpainlner K. The impact of pharmacogenetics and pharmacogcnomics on drug discovery. Nat Rev Drug Discov. 2002; 1 (6): 463–9. DOI: 10.1038/nrd823
  17. Oganov R.G., Simanenkov V.I., Bakulin I.G. et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention. 2019; 18 (1): 5–66 (in Russ.). DOI: 10.15829/1728-8800-2019-1-5-66
  18. Khidirova L.D., Yakhontov D.A., Zenin S.A. Atrial fibrillation in comorbid patients depending on the treatment regimen. Complex Issues of Cardiovascular Diseases. 2019; 8 (2): 21–9 (in Russ.). DOI: 10.17802/2306-1278-2019-8-2-21-29
  19. Khidirova L.D., Yakhontov D.A., Zenin S.A. et al. Features of Atrial Fibrillation in Patients with Arterial Hypertension and Extracardial Disorders. Rational Pharmacotherapy in Cardiology. 2019; 15 (3): 368–73 (in Russ.). DOI: 10.20996/1819-6446-2019-15-3-368-373